160 related articles for article (PubMed ID: 16640958)
1. Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
Rosenson RS
Curr Atheroscler Rep; 2006 May; 8(3):219-22. PubMed ID: 16640958
[No Abstract] [Full Text] [Related]
2. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
3. Combination lipid therapy in type 2 diabetes.
Sacks FM; Carey VJ; Fruchart JC
N Engl J Med; 2010 Aug; 363(7):692-4; author reply 694-5. PubMed ID: 20842772
[No Abstract] [Full Text] [Related]
4. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
6. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
[TBL] [Abstract][Full Text] [Related]
7. Fibrates consistently lower risk of cardiovascular events across high-risk groups.
Aalbers J
Cardiovasc J Afr; 2010; 21(3):174. PubMed ID: 20532463
[No Abstract] [Full Text] [Related]
8. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
9. Fibrates: where are we now?
Seth Loomba R; Arora R
Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
[TBL] [Abstract][Full Text] [Related]
10. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
[TBL] [Abstract][Full Text] [Related]
11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
12. Retinopathy progression in type 2 diabetes.
Baum SJ
N Engl J Med; 2010 Nov; 363(22):2172; author reply 2173-4. PubMed ID: 21105808
[No Abstract] [Full Text] [Related]
13. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
[TBL] [Abstract][Full Text] [Related]
14. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Pruski M; Krysiak R; Okopien B
Diabetes Care; 2009 Aug; 32(8):1421-4. PubMed ID: 19435959
[TBL] [Abstract][Full Text] [Related]
16. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of fibrates.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Curr Atheroscler Rep; 2005 Sep; 7(5):396-401. PubMed ID: 16105484
[TBL] [Abstract][Full Text] [Related]
18. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Bruckert E; De Gennes JL; Malbecq W; Baigts F
Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
